Within the scope of the TÜBİTAK Center of Excellence Support Program (1004 Program), the project titled "Development of OMV-based H. pylori vaccine prototype" was supported under the supervision of Prof. Dr. Ayça Sayı Yazgan.  Alongside our university, the Protection and Treatment National Platform, led by the Izmir Biomedicine and Genome Center (IBG), includes several other universities and industrial organizations, such as Middle East Technical University, Dokuz Eylül University, Ege University, Selçuk University, ATABAY KİMYA SAN. VE TİC. AŞ., PETROYAĞ VE KİMYASALLARI SAN. VE TİC. AŞ.

Gastric cancer is the leading cause of death in cancer types worldwide. Helicobacter pylori (H.pylori) has been identified as one of the most important risk factors for the development of gastric cancer. In developing countries, including Turkey, 80% of individuals are infected with H.pylori. However, only 20% of infected individuals show gastric complications such as gastritis, ulcers, or gastric cancer. With this project; after the completion of the advanced phase studies of the H. pylori vaccine prototype Prof. Dr. Ayça Sayı Yazgan and the collaborating researchers aim to develop, a preventive prophylactic vaccine to be released in other countries of the developing world.